Value of KidneyIntelX Testing Demonstrated by Data from 401 Physician Study Presented at National Kidney Foundation 2021 Spring Clinical Meetings NEW YORK, April 08, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) announces findings presented in a Late-Breaking presentation at
RNS Number : 7571U Renalytix AI PLC 08 April 2021 Renalytix AI plc (" RenalytixAI " or the " Company ") Clinical Utility Study Demonstrates Primary Care Physicians Highly Likely to Order KidneyIntelX to Inform Care Decisions Value of KidneyIntelX Testing Demonstrated by Data from 401
RNS Number : 4091U Renalytix AI PLC 06 April 2021 Renalytix AI plc (" RenalytixAI " or the " Company ") Multi-Center Study Finds KidneyIntelX 72% More Effective Than Current Standard of Care In Identifying Early-Stage Patients at High Risk for Kidney Disease Progression and Failure
Clinical findings published in the April issue of Diabetologia, the official journal of the European Association for the Study of Diabetes NEW YORK, April 05, 2021 (GLOBE NEWSWIRE) -- RenalytixAI plc (LSE: RENX) (NASDAQ: RNLX), announced today that KidneyIntelX™ more accurately predicted
NEW YORK, March 15, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, provides an update
RNS Number : 1874S Renalytix AI PLC 15 March 2021 Renalytix AI plc (" RenalytixAI " or the " Company ") Update on Finalization of MCIT Rule to Provide National Medicare Coverage for FDA Breakthrough Devices and Diagnostics NEW YORK , March 15, 2021 - Renalytix AI plc (LSE : RENX) (NASDAQ:
NEW YORK, March 04, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces that
RNS Number : 2460R Renalytix AI PLC 04 March 2021 Renalytix AI plc ("RenalytixAI", the "Company" or the "Group") Issue of shares under the 2020 Employee Share Purchase Plan, PDMR Dealing and Total Voting Rights New York , 4 March 2021 - Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX),, an
NEW YORK, March 02, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) (“RenalytixAI” or the “Company”), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance
RNS Number : 8363Q Renalytix AI PLC 02 March 2021 RenalytixAI Reports Financial Results for Second Quarter of Fiscal Year 2021 NEW YORK , March 2, 2021 - Renalytix AI plc (LSE : RENX) (NASDAQ: RNLX) ("RenalytixAI" or the "Company"), an artificial intelligence-enabled in vitro diagnostics